Illumina (ILMN)
(Delayed Data from NSDQ)
$124.39 USD
-5.37 (-4.14%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $123.86 -0.53 (-0.43%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth D Momentum D VGM
Illumina (ILMN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$148.78 | $242.00 | $100.00 | 14.66% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Illumina comes to $148.78. The forecasts range from a low of $100.00 to a high of $242.00. The average price target represents an increase of 14.66% from the last closing price of $129.76.
Analyst Price Targets (23)
Broker Rating
Illumina currently has an average brokerage recommendation (ABR) of 1.91 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 2.20 a month ago based on 20 recommendations.
Of the 22 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 54.55% and 4.55% of all recommendations. A month ago, Strong Buy made up 45%, while Buy represented 5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ILMN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 9 | 9 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 8 | 8 | 8 | 8 | 9 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 1 | 1 | 1 |
ABR | 1.91 | 1.91 | 2.20 | 2.20 | 2.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/4/2024 | Canaccord Genuity | Kyle Mikson | Hold | Hold |
8/28/2024 | Argus Research Corp. | Jasper Hellweg | Not Available | Strong Buy |
8/16/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
8/15/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
8/14/2024 | Cowen & Co. | Daniel Brennan | Hold | Strong Buy |
8/14/2024 | Not Identified | Not Identified | Strong Sell | Hold |
8/7/2024 | Robert W. Baird & Co. | Catherine W Schulte | Hold | Hold |
8/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/7/2024 | UBS | John N Sourbeer | Hold | Hold |
7/30/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
7/10/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Hold | Strong Buy |
6/20/2024 | Guggenheim Securities | Subbu Nambi | Strong Buy | Strong Buy |
6/11/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
6/6/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Hold |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/16/2024 | Not Identified | Not Identified | Strong Buy | Hold |
12/15/2023 | Not Identified | Not Identified | Strong Sell | Hold |
12/13/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.91 |
ABR (Last week) | 1.91 |
# of Recs in ABR | 22 |
Average Target Price | $148.78 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 253 |
Current Quarter EPS Est: | 0.87 |
ILMN FAQs
Illumina, Inc. (ILMN) currently has an average brokerage recommendation (ABR) of 1.91 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms.
The average price target for Illumina, Inc. (ILMN) is $148.78. The current on short-term price targets is based on 6 reports.
The forecasts for Illumina, Inc. (ILMN) range from a low of $100 to a high of $242. The average price target represents a increase of $19.61 from the last closing price of $124.39.
The current UPSIDE for Illumina, Inc. (ILMN) is 19.61%
Based on short-term price targets offered by 23 analysts, the average price target for Illumina comes to $148.78. The forecasts range from a low of $100.00 to a high of $242.00. The average price target represents an increase of 14.66% from the last closing price of $129.76.